
==== Front
Heliyon
Heliyon
Heliyon
2405-8440
Elsevier

S2405-8440(24)11991-3
10.1016/j.heliyon.2024.e35960
e35960
Review Article
Current knowledge of antisense long non-coding RNA in the occurrence and prognosis of skull base tumors
Zhang Han ab
Lv Qingwei a
Zheng Ziqiang a
Shen Liangjun a
Zhou Jing a
Xu Qishen a
Guo Mi szguomi123@sohu.com
ab⁎
a Department of Neurosurgery, Shengzhou People's Hospital (the First Affiliated Hospital of Zhejiang University Shengzhou Branch), Shengzhou, Zhejiang, China
b The Shengzhou Hospital of Shaoxing University, Shengzhou, Zhejiang, China
⁎ Corresponding author. Department of Neurosurgery, Shengzhou People's Hospital (the First Affiliated Hospital of Zhejiang University Shengzhou Branch), Shengzhou, Zhejiang, China. szguomi123@sohu.com
08 8 2024
30 8 2024
08 8 2024
10 16 e3596020 4 2023
6 8 2024
6 8 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Antisense long non-coding RNA (AS-lncRNA) represents a novel class of RNA molecules. In recent years, it has been discovered that AS-lncRNAs play crucial roles in various biological processes, particularly in the onset and progression of tumors. Skull base tumors, originating from the base of the brain, exhibit specific expression patterns of AS-lncRNA which correlate significantly with clinical characteristics. This makes AS-lncRNA a promising candidate as a tumor marker. Functional studies have revealed that AS-lncRNAs can regulate gene expression by acting as miRNA sponges and interacting with RBPs. Consequently, they play pivotal roles in tumor cell cycle, apoptosis, angiogenesis, invasion, and metastasis processes. Further exploration into the mechanisms of AS-lncRNA in tumors holds substantial theoretical significance for deeper insights into the etiology, pathogenesis, and RNA dynamics of skull base tumors. Moreover, AS-lncRNA could serve as molecular markers or potential targets for early diagnosis. Their potential extends to efficacy assessment, prognosis prediction, and gene therapy, suggesting broad clinical applications. In summary, AS-lncRNA emerges as a promising molecular marker implicated in the onset and progression of skull base tumors.

Keywords

Skull base tumor
Antisense lncRNA
Biomarker
Metastasis
Gene therapy
==== Body
pmc1 Introduction

Long noncoding RNAs (lncRNAs), RNA molecules exceeding 200 bp in length and lacking protein-coding capacity, have gained significant attention in biomedical research in recent years. They regulate gene expression at pre-transcriptional, transcriptional, and post-transcriptional levels, influencing various biological processes [1,2]. Among them, antisense lncRNA (AS-lncRNA) represent a significant subgroup formed by transcription from antisense strands of protein-coding or noncoding RNA genes [3,4]. AS-lncRNA have been found to play diverse roles in intracellular physiology and pathology, contributing significantly to the pathogenesis of various diseases such as malignant tumors and Parkinson's disease [[5], [6], [7], [8]].

Skull base tumors originate from the base of the brain, encompassing tissues above, within, and below the skull base bones. These tumors can extend cephalically, invading the skull, and caudally, affecting areas such as the orbit, sinuses, nasal cavity, infratemporal fossa, and parapharyngeal space [[9], [10], [11]]. The spectrum of tumors and tumor-like lesions in this region includes nasopharyngeal carcinoma, chordoma, pituitary tumors, sarcomas, and meningiomas, with current treatment primarily relying on a combination of surgery and radiotherapy [12,13]. However, due to the nascent nature of this field, a comprehensive understanding of the etiology and progression of most skull base tumors remains elusive.

In this review, we aimed to summarize current research on AS-lncRNA in skull base tumors, explore their potential as molecular markers for tumors, and elucidate the mechanisms through which representative AS-lncRNA exert their functions. It is anticipated that this review will inspire new avenues and insights for future research on skull base tumors.

1.1 AS-lncRNA as a potential biomarker in skull base tumors

AS-lncRNA are implicated in crucial tumor development processes due to their unique structural properties, suggesting their potential as novel molecular markers for tumors. Therefore, qRT-PCR and in situ hybridization were initially employed to assess AS-lncRNA expression in cancer tissues from patients. Analysis of clinical data revealed significant associations between various AS-lncRNA and the clinicopathological stages of skull base tumors. For instance, elevated AFAP1-AS1 expression correlated closely with overall survival (OS), recurrence-free survival (RFS), and lymphatic metastasis across tumors such as nasopharyngeal carcinoma [[14], [15], [16], [17], [18], [19]]. Conversely, increased HNF1A-AS1 expression was strongly linked to TNM stage (T: Tumor (Topography), N:Lymph Node, M: Metastasis), tumor size, and lymphatic metastasis in cancers like esophageal, gastric, and lung cancer [20,21]. Similarly, high expression levels of HOXA-AS2, ANRIL, and ZEB1-AS1 were associated with overall survival, recurrence-free survival, and clinical stage in nasopharyngeal carcinoma and other cancer types [[22], [23], [24], [25], [26]]. These findings underscore the potential of AS-lncRNA as valuable tumor markers. RNA sequencing of skull base tumors, including nasopharyngeal carcinoma, further revealed distinct and specific AS-lncRNA expression patterns across various aggressive tumors such as pituitary tumors and chordoma. Nonetheless, comprehensive functional studies are currently lacking, necessitating further investigation (Table 1).Table 1 Antisense long noncoding RNAs serve as novel biomarkers in skull base tumor.

Table 1antisense lncRNA	Host gene	tumor type	relative clinical characters	
CLRN1-AS1	CLRN1	Pituitary adenoma	OS; High in tumor	
AFAP1-AS1	AFAP1	NPC	OSa lymph node metastasis	
HOTAIR	HOXA	NPC	OS; RFS; metastasis	
HOXA-AS2	HOXA	NPC	OS; metastasis	
OIP5-AS1	OIP5	NPC	OS	
HOXA11-AS	HOXA11	NPC	cisplatin drug resistance	
TMPO-AS1	CTBP	NPC	OS; TNM stage	
FOXD3-AS1	FOXD3	NPC	lymph node metastasis; tumor size	
MSC-AS1	MSC	NPC	TNM stage; tumor size; lympg nodemetastasis	
MACC1-AS1	MACC1	NPC	High expression in tumor	
ZFAS1	HOXC	NPC	High expression in tumor	
HOXC13-AS	HOXC13	NPC	OS	
CDKN2B-AS1 et al.	CDKN2B	Chordoma	High expression in tumor	
HAM1	HOX	ACC	RFS	
NPC: nasophagenal carcinoma.

ACC.

**RFS: recurrence free survival.

a OS: overall survival.

2 Molecular mechanisms of AS-lncRNA in tumor development

Further mechanistic studies have revealed that AS-lncRNA can regulate tumors in various ways. Some inhibit the expression of their antisense counterparts, while others, similar to other non-coding RNAs, modulate target gene expression through ceRNA interactions with miRNAs and binding to RNA-binding proteins (Fig. 1).Fig. 1 Schematic representation of antisense long-stranded non-coding RNA function in skull base tumors. Antisense lncRNA regulate malignant phenotypes such as tumor proliferation and invasive metastasis by binding miRNAs, binding proteins and other modes.

Fig. 1

2.1 AFAP1-AS1

AFAP1-AS1 is an AS-lncRNA transcribed from the antisense strand of the AFAP1 gene. It has been found significantly upregulated in various tumors, including nasopharyngeal carcinoma, lung, and pancreatic cancers, correlating with poor patient prognosis [[27], [28], [29], [30]]. Proteomic and bioinformatics analyses have shown that AFAP1-AS1 alters cytoskeletal composition, particularly actin dynamics in nasopharyngeal carcinoma. Moreover, AFAP1-AS1 promotes cancer cell invasion and metastasis through the Rho/Rac signaling pathway [14,17]. Additionally, AFAP1-AS1 enhances tongue cancer cell proliferation, although the precise mechanism remains unclear.

2.2 HNF1A-AS1

HNF1A-AS1, a 2455 bp antisense RNA transcribed from the antisense strand of HNF1A, exhibits significantly lower overall survival rates in patients with high expression levels in esophageal and gastric cancers, as well as lung adenocarcinoma, as determined by gene chip analysis [31,32]. Mechanistic investigations have revealed that HNF1A-AS1 promotes tumor invasion and metastasis by upregulating cyclin D1, E-cadherin, N-cadherin, and β-catenin expression [33,34].

2.3 ZFAS1

ZFAS1, an AS-lncRNA, has gained attention in recent years for its role in various tumors, including hepatocellular carcinoma and nasopharyngeal carcinoma, potentially serving as a molecular marker. Mechanistic studies have identified the role of ZFAS1 in regulating several signaling pathways such as PI3K-Akt and WNT pathways by modulating miR-7, miR 135, and miR892b, thereby promoting invasive metastasis and proliferation in nasopharyngeal carcinoma.

2.4 HOTAIR and HOXA-AS2

HOTAIR is an AS-lncRNA transcribed from the antisense strand of the HOXC gene. Numerous studies have demonstrated that high HOTAIR expression is associated with poor prognosis in various cancers, including breast, gastric, esophageal, and laryngeal cancers [[35], [36], [37]]. Further investigations indicate that HOTAIR primarily regulates genes like WIF1, PTEN, and p21 by modulating histone H3K27me3 (histone H3 tri-methylated at lysine 27), thereby inhibiting tumor cell apoptosis and promoting tumor angiogenesis and invasion through downstream signaling pathways such as Wnt, Akt, and p53 [[38], [39], [40]].

Clinical analyses have linked HOXA-AS2 closely with adverse prognosis and clinical profiles in patients with NPC and other tumors [22]. Mechanistic studies reveal that HOXA-AS2 promotes gastric cancer cell proliferation by interacting with EZH2 to downregulate expression of P21, PLK3, and DDIT3 [41,42].

2.5 ANRIL

ANRIL (CDKN2B-AS1) is a 3.8-kb AS-lncRNA transcribed from the antisense strand of CDKN2B. Clinical data from various cancer patients, including gastric cancer, show that high ANRIL expression correlates significantly with reduced overall survival and advanced clinical stage [[23], [24], [25]]. Mechanistic studies indicate the role of ANRIL in promoting tumor cell proliferation by binding to miR-99a and miR-449a, thereby regulating the mTOR pathway and CDK6/E2F1 pathway through ceRNA mechanisms [43,44].

2.6 Other AS-lncRNA

In addition to the aforementioned AS-lncRNA, several others have been identified in tumors. p53-as is a recently discovered AS-lncRNA that downregulates p53 and p21 expression, thereby promoting tumor development, though its exact mechanism remains unclear. Similarly, p15-as and LINCp21, derived from antisense strand transcription of p15 and p21, contribute to tumor development by downregulating p15 and p21, necessitating further investigation into their specific molecular mechanisms [45]. Conversely, MDC1-AS upregulates MDC1 gene expression, suggesting additional studies are needed to elucidate the functions of these AS-lncRNA.

3 Discussion

AS-lncRNA represent a recently discovered class of RNA molecules. They are recognized not as products of transcriptional errors but as a burgeoning research focus within the realm of long-strand non-coding RNAs due to their significant biological functions [45]. Various proteins and miRNAs have been implicated in the post-transcriptional regulation involved in the processing of RNA precursors into AS-lncRNA [46,47]. However, the regulatory factors and mechanisms governing the production of these RNAs remain poorly understood, a matter of considerable interest. In clinical applications, AS-lncRNA have been detected and analyzed alongside clinical data. Many such RNAs, including AFAP1AS1, HNF1A-AS1, and HOXA-AS2, have been closely linked to TNM stage and overall survival time in malignant tumor patients. Their potential use as molecular markers and therapeutic targets for tumors is also a subject of significant interest.

Skull base tumors have recently gained increasing attention as one of the fastest-growing fields. Advances in surgical techniques, particularly endoscopic methods, have made surgical treatment of skull base tumors feasible. However, gaps persist in understanding the onset and progression of these tumors [48,49], posing a significant obstacle to improving treatment outcomes for skull base tumors.

There is abundant evidence indicating that lncRNA regulate gene expression at epigenetic, transcriptional, and post-transcriptional levels. Some of these RNAs can also directly encode proteins, thereby participating in the regulation of various physiological and pathological processes, including malignant tumors [50,51]. It has been demonstrated that a primary mechanism by which AS-lncRNA exert their biological functions is by acting as miRNA sponges. Specifically, they bind miRNAs, thereby regulating the expression of related genes through competitive endogenous RNA (ceRNA) mechanisms. The ceRNA regulatory network is further complicated by the presence of miRNA, lncRNA, mRNA, and their pseudogenes; the addition of circRNA enhances this complexity. Additionally, there may exist mutual regulatory relationships between circRNA and its antisense strand-derived mRNA or even lncRNA [52]. Moreover, recent findings indicate that lncRNAs can encode proteins, thus participating in physiological and pathological activities through their protein products. Whether AS-lncRNA employ similar mechanisms remains to be fully explored [53,54]. These discoveries contribute to a deeper understanding of intracellular RNA regulatory networks (i.e., RNA language) and further elucidate fundamental biological principles. However, AS-lncRNA have only garnered attention in recent years, with only a few dozen functionally reported thus far. In clinical applications, AS-lncRNA are closely linked to tumor development. They can serve as molecular markers for predicting tumor recurrence or assessing patient response to treatment in skull base tumors, aiding in the selection of appropriate treatment strategies. Furthermore, with the advancement of RNA vaccines, AS-lncRNA, as crucial RNA components, may be utilized to design future RNA vaccines targeting AS-lncRNA, potentially enhancing therapeutic efficacy against skull base tumors. However, the functions of the vast majority of AS-lncRNA remain inadequately explored, and unraveling their roles promises to deepen our understanding of life phenomena at its essence.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

CRediT authorship contribution statement

Han Zhang: Investigation, Conceptualization. Qingwei Lv: Software. Ziqiang Zheng: Writing – review & editing. Liangjun Shen: Writing – original draft. Jing Zhou: Writing – original draft. Qishen Xu: Data curation. Mi Guo: Investigation.

Declaration of competing interest

The authors declare that they have no competing interests.

Acknowledgements

Not applicable.
==== Refs
References

1 Li Y. Li W. Hoffman A.R. Cui J. Hu J.F. The nucleus/mitochondria-shuttling LncRNAs function as new epigenetic regulators of mitophagy in cancer Front. Cell Dev. Biol. 9 2021 699621
2 Peng W.X. Koirala P. Mo Y.Y. LncRNA-mediated regulation of cell signaling in cancer Oncogene 36 2017 5661 5667 28604750
3 Wang L. Cho K.B. Li Y. Tao G. Xie Z. Guo B. Long noncoding RNA (lncRNA)-Mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer Int. J. Mol. Sci. 20 22 2019 5758 31744051
4 Wang Y. Peng Z. Wang Y. Yang Y. Fan R. Gao K. Zhang H. Xie Z. Jiang W. Immune microenvironment change and involvement of circular RNAs in TIL cells of recurrent nasopharyngeal carcinoma Front. Cell Dev. Biol. 9 2021 722224
5 Cui X.Y. Zhan J.K. Liu Y.S. Roles and functions of antisense lncRNA in vascular aging Ageing Res. Rev. 2021 101480
6 Xu F. Huang M. Chen Q. Niu Y. Hu Y. Hu P. Chen D. He C. Huang K. Zeng Z. Tang J. Wang F. Zhao Y. Wang C. Zhao G. LncRNA HIF1A-AS1 promotes gemcitabine resistance of pancreatic cancer by enhancing glycolysis through modulating the AKT/YB1/HIF-1 alpha pathway Cancer Res. 81 22 2021 5678 5691 34593522
7 Nie H. Liao Z. Wang Y. Zhou J. He X. Ou C. Exosomal long non-coding RNAs: emerging players in cancer metastasis and potential diagnostic biomarkers for personalized oncology Genes Dis 8 6 2020 769 780 34522707
8 Ou C. He X. Liu Y. Zhang X. lncRNA cytoskeleton regulator RNA (CYTOR): diverse functions in metabolism, inflammation and tumorigenesis, and potential applications in precision oncology Genes Dis 23 10 2021 415 429
9 Soule E. Baig S. Fiester P. Holtzman A. Rutenberg M. Tavanaiepour D. Rao D. Current management and image review of skull base chordoma: what the radiologist needs to know J Clin Imaging Sci 11 2021 46 34513210
10 Hudgins P.A. Baugnon K.L. Head and neck: skull base imaging Neurosurgery 82 2018 255 267 29040722
11 Mehta G.U. Raza S.M. Management of skull base metastases Neurosurg Clin N Am 31 2020 659 666 32921360
12 Peng Z. Wang Y. Wang Y. Fan R. Gao K. Zhang H. Xie Z. Jiang W. Preliminary efficacy report and prognosis analysis of endoscopic endonasal nasopharyngectomy for recurrent nasopharyngeal carcinoma Front Surg 8 2021 713926
13 Gu Y. Zhou Q. Zhu W. Wu Q. Xie T. Wu S. Hu F. Yu Y. Sun C. Li C. Zhang B. Zhan L. Zhang X. The purely endoscopic supracerebellar infratentorial approach for resecting pineal region tumors with preservation of cerebellomesencephalic vein: technical note and preliminary clinical outcomes World Neurosurg 128 2019 e334 e339 31028986
14 Bo H. Gong Z. Zhang W. Li X. Zeng Y. Liao Q. Chen P. Shi L. Lian Y. Jing Y. Tang K. Li Z. Zhou Y. Zhou M. Xiang B. Li X. Yang J. Xiong W. Li G. Zeng Z. Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma Oncotarget 6 2015 20404 20418 26246469
15 Fang M. Zhang M. Wang Y. Wei F. Wu J. Mou X. Zhang Y. Liang X. Tang J. Long noncoding RNA AFAP1-AS1 is a critical regulator of nasopharyngeal carcinoma tumorigenicity Front. Oncol. 10 2020 601055
16 He B. Zeng J. Chao W. Chen X. Huang Y. Deng K. Huang Z. Li J. Dai M. Chen S. Huang H. Dai S. Serum long non-coding RNAs MALAT1, AFAP1-AS1 and AL359062 as diagnostic and prognostic biomarkers for nasopharyngeal carcinoma Oncotarget 8 2017 41166 41177 28467811
17 Lian Y. Xiong F. Yang L. Bo H. Gong Z. Wang Y. Wei F. Tang Y. Li X. Liao Q. Wang H. Zhou M. Xiang B. Wu X. Li Y. Li X. Chen X. Li G. Guo C. Zeng Z. Xiong W. Long noncoding RNA AFAP1-AS1 acts as a competing endogenous RNA of miR-423-5p to facilitate nasopharyngeal carcinoma metastasis through regulating the Rho/Rac pathway J. Exp. Clin. Cancer Res. : CR. 37 2018 253 30326930
18 Tang Y. He Y. Shi L. Yang L. Wang J. Lian Y. Fan C. Zhang P. Guo C. Zhang S. Gong Z. Li X. Xiong F. Li X. Li Y. Li G. Xiong W. Zeng Z. Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma Oncotarget 8 2017 39001 39011 28380458
19 Wei F. Jing Y.Z. He Y. Tang Y.Y. Yang L.T. Wu Y.F. Tang L. Shi L. Gong Z.J. Guo C. Zhou M. Xiang B. Li X.L. Li Y. Li G.Y. Xiong W. Zeng Z.Y. Xiong F. Cloning and characterization of the putative AFAP1-AS1 promoter region J. Cancer 10 2019 1145 1153 30854123
20 Wang Z. Liu L. Du Y. Mi Y. Wang L. The HNF1A-AS1/miR-92a-3p axis affects the radiosensitivity of non-small cell lung cancer by competitively regulating the JNK pathway Cell biology and toxicology 37 2021 715 729 33755848
21 Xue J. Bai J. Long Q. Wei Y. Pan J. Li X. Tang Q. TCF-3-mediated transcription of lncRNA HNF1A-AS1 targeting oncostatin M expression inhibits epithelial-mesenchymal transition via TGFβ signaling in gastroenteropancreatic neuroendocrine neoplasms Aging 13 2021 14065 14077 34037532
22 Wang S. You H. Yu S. Long non-coding RNA HOXA-AS2 promotes the expression levels of hypoxia-inducible factor-1α and programmed death-ligand 1, and regulates nasopharyngeal carcinoma progression via miR-519 Oncol. Lett. 20 2020 245 32973958
23 Hu X. Jiang H. Jiang X. Downregulation of lncRNA ANRIL inhibits proliferation, induces apoptosis, and enhances radiosensitivity in nasopharyngeal carcinoma cells through regulating miR-125a Cancer Biol. Ther. 18 2017 331 338 28402230
24 Wang Y. Cheng N. Luo J. Downregulation of lncRNA ANRIL represses tumorigenicity and enhances cisplatin-induced cytotoxicity via regulating microRNA let-7a in nasopharyngeal carcinoma J. Biochem. Mol. Toxicol. 31 7 2017 e21904
25 Zou Z.W. Ma C. Medoro L. Chen L. Wang B. Gupta R. Liu T. Yang X.Z. Chen T.T. Wang R.Z. Zhang W.J. Li P.D. LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing side-population stem-like cancer cells Oncotarget 7 2016 61741 61754 27557514
26 Wang X. Guo Y. Wang C. Wang Q. Yan G. Long noncoding RNA ZEB1-AS1 downregulates miR-23a, promotes tumor progression, and predicts the survival of oral squamous cell carcinoma patients OncoTargets Ther. 14 2021 2699 2710
27 Bi Z. Li Q. Dinglin X. Xu Y. You K. Hong H. Hu Q. Zhang W. Li C. Tan Y. Xie N. Ren W. Li C. Liu Y. Hu H. Xu X. Yao H. Nanoparticles (NPs)-Meditated LncRNA AFAP1-AS1 silencing to block wnt/β-catenin signaling pathway for synergistic reversal of radioresistance and effective cancer radiotherapy Adv. Sci. 7 2020 2000915
28 Han M. Gu Y. Lu P. Li J. Cao H. Li X. Qian X. Yu C. Yang Y. Yang X. Han N. Dou D. Hu J. Dong H. Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation Mol. Cancer 19 1 2020 26 32020881
29 Liu Y. Hu Q. Wang X. AFAP1-AS1 induces cisplatin resistance in non-small cell lung cancer through PI3K/AKT pathway Oncol. Lett. 19 2020 1024 1030 31897216
30 Mi X. Xu R. Hong S. Xu T. Zhang W. Liu M. M2 macrophage-derived exosomal lncRNA AFAP1-AS1 and MicroRNA-26a affect cell migration and metastasis in esophageal cancer Mol. Ther. Nucleic Acids 22 2020 779 790 33230475
31 Liu H.T. Liu S. Liu L. Ma R.R. Gao P. EGR1-Mediated transcription of lncRNA-hnf1a-AS1 promotes cell-cycle progression in gastric cancer Cancer Res. 78 2018 5877 5890 30185552
32 Luo X. Wei J. Yang F.L. Pang X.X. Shi F. Wei Y.X. Liao B.Y. Wang J.L. Exosomal lncRNA HNF1A-AS1 affects cisplatin resistance in cervical cancer cells through regulating microRNA-34b/TUFT1 axis Cancer Cell Int. 19 2019 1 12 30622437
33 Meng Q. Wang L. Lv Y. Wu J. Shi W. Deletion of HNF1A-AS1 suppresses the malignant phenotypes of breast cancer cells in vitro and in vivo through targeting miRNA-20a-5p/TRIM32 Axis Cancer Biother. Rad. 36 2021 23 35
34 Wu J. Meng X. Jia Y. Chai J. Wang J. Xue X. Dang T. Long non-coding RNA HNF1A-AS1 upregulates OTX1 to enhance angiogenesis in colon cancer via the binding of transcription factor PBX3 Exp. Cell Res. 393 2020 112025
35 Nie Y. Liu X. Qu S. Song E. Zou H. Gong C. Long non-coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival Cancer Sci. 104 2013 458 464 23281836
36 Yang F.L. Wei Y.X. Liao B.Y. Wei G.J. Qin H.M. Pang X.X. Wang J.L. LncRNA HOTAIR regulates the expression of E-cadherin to affect nasopharyngeal carcinoma progression by recruiting histone methylase EZH2 to mediate H3K27 trimethylation Genomics 113 2021 2276 2289 33965547
37 Yu Y. Zhang X. Li Z. Kong L. Huang Y. LncRNA HOTAIR suppresses TNF-α induced apoptosis of nucleus pulposus cells by regulating miR-34a/Bcl-2 axis Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 107 2018 729 737 30138895
38 Fu W.M. Lu Y.F. Hu B.G. Liang W.C. Zhu X. Yang H.D. Li G. Zhang J.F. Long noncoding RNA Hotair mediated angiogenesis in nasopharyngeal carcinoma by direct and indirect signaling pathways Oncotarget 7 2016 4712 4723 26717040
39 Hu W. Xu W. Shi Y. Dai W. lncRNA HOTAIR upregulates COX-2 expression to promote invasion and migration of nasopharyngeal carcinoma by interacting with miR-101 Biochem. Biophys. Res. Commun. 505 2018 1090 1096 30314699
40 Ma D.D. Yuan L.L. Lin L.Q. LncRNA HOTAIR contributes to the tumorigenesis of nasopharyngeal carcinoma via up-regulating FASN Eur. Rev. Med. Pharmacol. Sci. 21 2017 5143 5152 29228426
41 Wang J. Su Z. Lu S. Fu W. Liu Z. Jiang X. Tai S. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer Clinica chimica acta; international journal of clinical chemistry 485 2018 229 233 29981289
42 Xiao S. Song B. LncRNA HOXA-AS2 promotes the progression of prostate cancer via targeting miR-509-3p/PBX3 axis Biosci. Rep. 40 8 2020 BSR20193287
43 Deng W. Zhang Y. Cai J. Zhang J. Liu X. Yin J. Bai Z. Yao H. Zhang Z. LncRNA-ANRIL promotes gastric cancer progression by enhancing NF-kB signaling Exp. Biol. Med. (Maywood, NJ, U. S.) 244 2019 953 959
44 Kong Y. Hsieh C.H. Alonso L.C. ANRIL: a lncRNA at the CDKN2A/B locus with roles in cancer and metabolic disease Front. Endocrinol. 9 2018 405
45 Melo C.A. Léveillé N. Rooijers K. Wijchers P.J. Geeven G. Tal A. Melo S.A. de Laat W. Agami R. A p53-bound enhancer region controls a long intergenic noncoding RNA required for p53 stress response Oncogene 35 2016 4399 4406 26776159
46 Lu C.W. Zhou D.D. Xie T. Hao J.L. Pant O.P. Lu C.B. Liu X.F. HOXA11 antisense long noncoding RNA (HOXA11-AS): a promising lncRNA in human cancers Cancer Med. 7 2018 3792 3799 29992790
47 Maruyama R. Yokota T. Knocking down long noncoding RNAs using antisense oligonucleotide gapmers Methods Mol. Biol. 2176 2020 49 56 32865781
48 Mo Y. Wang Y. Zhang S. Xiong F. Yan Q. Jiang X. Deng X. Wang Y. Fan C. Tang L. Zhang S. Gong Z. Wang F. Liao Q. Guo C. Li Y. Li X. Li G. Zeng Z. Xiong W. Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2 Mol. Cancer 20 1 2021 1 21 33386068
49 Peng Z. Wang Y. Wang Y. Fan R. Gao K. Zhang H. Jiang W. Comparing the effectiveness of endoscopic surgeries with intensity-modulated radiotherapy for recurrent rT3 and rT4 nasopharyngeal carcinoma: a meta-analysis Front. Oncol. 11 2021 703954
50 Jiang W. Pan S. Chen X. Wang Z.W. Zhu X. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy Mol. Cancer 20 1 2021 1 17 33386068
51 Ling X. Han Y. Meng J. Zhong B. Chen J. Zhang H. Qin J. Pang J. Liu L. Small extrachromosomal circular DNA (eccDNA): major functions in evolution and cancer Mol. Cancer 20 1 2021 1 15 33386068
52 Pan C. Li B. Simon M.C. Moonlighting functions of metabolic enzymes and metabolites in cancer Mol. Cell 81 2021 3760 3774 34547237
53 He L. Man C. Xiang S. Yao L. Wang X. Fan Y. Circular RNAs' cap-independent translation protein and its roles in carcinomas Mol. Cancer 20 1 2021 1 11 33386068
54 Balayan V. Guddati A.K. Tumor dormancy: biologic and therapeutic implications World J. Oncol. 13 1 2022 8 19 35317328
